Identifying Disparities in Type 2 Diabetes Among Asian Americans: The Pan Asian C

确定亚裔美国人 2 型糖尿病的差异：泛亚裔 C

• 批准号: 7837912
• 负责人: Latha P Palaniappan
• 金额: $ 55.79万
• 依托单位: PALO ALTO MEDICAL FOUNDATION RES INST
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-25 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7837912
• 关键词: 2,4-thiazolidinedione; Address; Adult; Advocate; Affect; Age; Asian Americans; Asian Indian; Asians; Body Weight; Body Weight decreased; Body mass index; California; Caring; Chinese People; Chronic Disease; Clinical; Clinical effectiveness; Cohort Studies; Complications of Diabetes Mellitus; Data; Databases; Diabetes Mellitus; Diabetic Nephropathy; Diabetic Retinopathy; Effectiveness; Electronic Health Record; Ethnic Origin; Ethnic group; Filipino; Funding; Gender; Genetic; Goals; Healthcare Systems; Hemoglobin; High Density Lipoprotein Cholesterol; High Prevalence; Human Resources; Impact evaluation; Insulin Resistance; Insurance Coverage; Japanese Population; Knowledge; Koreans; Life; Link; Metabolic; Metformin; Minority Groups; Morbidity - disease rate; Myocardial Infarction; NIH Program Announcements; Non-Insulin-Dependent Diabetes Mellitus; Not Hispanic or Latino; Obesity; Oral; Pan Genus; Patients; Pharmaceutical Preparations; Pharmacists; Pharmacotherapy; Physicians; Population; Public Health; Race; Recovery; Research; Risk; Risk Factors; Role; Sampling; Stroke; Subgroup; Thiazolidinediones; Triglycerides; United States; United States National Institutes of Health; clinical care; cohort; comparative; comparative effectiveness; compare effectiveness; cost; cost effectiveness; diabetic; follow-up; health disparity; improved; parent grant; preference; prospective; public health relevance; response; treatment response

DESCRIPTION (provided by applicant): The revision to the parent grant, 5 R01 DK081371-02: "Identifying Disparities in Type 2 Diabetes Among Asian Americans: The Pan Asian Cohort Study," is in response to NOT-OD-09-058: "NIH Announces the Availability of Recovery Act Funds for Competitive Revision Applications." The parent grant is funded from January 15, 2009 - December 31, 2013 in response to Program Announcement PA-07-388: "Identifying and Reducing Diabetes and Obesity Related Health Disparities within Healthcare Systems (R01)." This five-year study addresses the lack of knowledge regarding type 2 diabetes and obesity in Asian Americans, both as an aggregate group and as distinct subgroups. Relatively little is known about how Asian subgroups differ in type 2 diabetes riskfactors and complications when compared to the Non-Hispanic White population, for which numerous study findings have informed both practice of care and public health efforts in the United States. The parent grant utilizes a mixed historical and prospective longitudinal cohort to address these research questions of significant public health import, linking existing clinical databases to construct a large (140,000 Asian adults) cohort of a multiethnic sample of contemporary Asians in California. The revision, a two-year study, aims to additionally compare the effectiveness of oral drugs for treatment of type 2 diabetes among Asian subgroups in the same electronically linked cohort. It is well-known that type 2 diabetes manifests differently in race/ethnic groups, and that race/ethnic groups respond differently to the same pharmacotherapy. Treatment options for type 2 diabetes are numerous, and previous studies have demonstrated differences in metabolic responses to certain oral drugs according to race/ethnicity. This creates a need for more race/ethnic specific data comparing the effects of medication use to be able to improve diabetes care in Asian Americans in the United States. The wealth of real-life data captured within the clinical cohort will be utilized to compare the effectiveness of oral drugs to treat type 2 diabetes among Asian subgroups and to study existing preferences for certain drugs among patients and physicians. Predictors of initial choice of oral drug (in physicians and patients), intermediate and long-term effectiveness of existing oral drugs on type 2 diabetes and its complications, and the cost-effectiveness of these therapies will be investigated under this competitive revision. This revision will contribute valuable knowledge for physicians, patients, and public health advocates on the clinical and cost effectiveness of various oral type 2diabetes therapies in Asian Americans. PUBLIC HEALTH RELEVANCE: Asian Americans (Asian Indian, Chinese, Filipino, Japanese, Korean, and Vietnamese) are disproportionately affected by type 2 diabetes. There is no data on comparative effectiveness of oral drugs to treat type 2 diabetes in Asian American subgroups. Our study will address this gap in knowledge.

说明（由申请人提供）：对家长补助金 5 R01 DK081371-02 的修订：“确定亚裔美国人中 2 型糖尿病的差异：泛亚队列研究”是对 NOT-OD-09-058 的回应： “NIH 宣布为竞争性修订申请提供恢复法案资金。”家长补助金的资助期限为 2009 年 1 月 15 日至 2013 年 12 月 31 日，以响应计划公告 PA-07-388：“识别和减少医疗保健系统内与糖尿病和肥胖相关的健康差异 (R01)”。这项为期五年的研究解决了亚裔美国人（无论是作为一个总体群体还是作为不同的亚群体）对 2 型糖尿病和肥胖症缺乏了解的问题。与非西班牙裔白人群体相比，我们对亚洲亚群体在 2 型糖尿病危险因素和并发症方面有何不同知之甚少，大量研究结果为美国的护理实践和公共卫生工作提供了信息。家长资助利用混合历史和前瞻性纵向队列来解决这些具有重要公共卫生意义的研究问题，连接现有的临床数据库以构建一个大型（140,000 名亚洲成年人）加利福尼亚州当代亚洲人多种族样本队列。此次修订是一项为期两年的研究，旨在进一步比较同一电子连接队列中亚洲亚组中口服药物治疗 2 型糖尿病的有效性。众所周知，2 型糖尿病在种族/族裔群体中表现不同，并且种族/族裔群体对相同药物治疗的反应也不同。 2 型糖尿病的治疗选择有很多，之前的研究已经证明，不同种族/民族对某些口服药物的代谢反应存在差异。这就需要更多的种族/民族特定数据来比较药物使用的效果，以便能够改善美国亚裔美国人的糖尿病护理。临床队列中获取的大量真实数据将用于比较亚洲亚组中口服药物治疗 2 型糖尿病的有效性，并研究患者和医生对某些药物的现有偏好。此次竞争性修订将研究口服药物的初始选择（医生和患者）、现有口服药物对 2 型糖尿病及其并发症的中长期疗效以及这些疗法的成本效益的预测因素。此次修订将为医生、患者和公共卫生倡导者提供有关亚裔美国人各种口服 2 型糖尿病疗法的临床和成本效益的宝贵知识。 公共卫生相关性：亚裔美国人（亚裔印度人、中国人、菲律宾人、日本人、韩国人和越南人）受 2 型糖尿病的影响尤为严重。目前尚无亚裔美国人亚群体口服药物治疗 2 型糖尿病的比较疗效数据。我们的研究将解决这一知识差距。